Combatting bacterial infections by killing persister cells with mitomycin C

Environmental Microbiology

Volumn 17, Issue 11, 2015, Pages 4406-4414

  Kwan, Brian W ^a   Chowdhury, Nityananda ^a   Wood, Thomas K ^a,b  

^a The Pennsylvania State University   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; CIPROFLOXACIN; CROSS LINKING REAGENT; MITOMYCIN;

ANIMAL; BIOFILM; CAENORHABDITIS ELEGANS; CYSTIC FIBROSIS; DISEASE MODEL; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI K 12; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIOLOGY; MULTIDRUG RESISTANCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

AMPICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; BIOFILMS; CAENORHABDITIS ELEGANS; CIPROFLOXACIN; CROSS-LINKING REAGENTS; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI K12; HUMANS; MITOMYCIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84949314419     PISSN: 14622912     EISSN: 14622920     Source Type: Journal    
DOI: 10.1111/1462-2920.12873     Document Type: Article

References (38)

1. Allison, K.R., Brynildsen, M.P., and Collins, J.J. (2011) Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 473: 216-220.
2. Ayrapetyan, M., Williams, T.C., and Oliver, J.D. (2015) Bridging the gap between viable but non-culturable and antibiotic persistent bacteria. Trends Microbiol 23: 7-13.
3. Balaban, N.Q., Merrin, J., Chait, R., Kowalik, L., and Leibler, S. (2004) Bacterial persistence as a phenotypic switch. Science 305: 1622-1625.
4. Bigger, J.W. (1944) Treatment of staphylococcal infections with penicillin by intermittent sterilisation. Lancet 244: 497-500.
5. Bradner, W.T. (2001) Mitomycin C: a clinical update. Cancer Treat Rev 27: 35-50.
6. Byfield, J.E., and Calabro-Jones, P.M. (1981) Carrier-dependent and carrier-independent transport of anti-cancer alkylating agents. Nature 294: 281-283.
7. Chen, X., Zhang, M., Zhou, C., Kallenbach, N.R., and Ren, D. (2011) Control of bacterial persister cells by Trp/Arg-containing antimicrobial peptides. Appl Environ Microbiol 77: 4878-4885.
8. Conlon, B.P., Nakayasu, E.S., Fleck, L.E., LaFleur, M.D., Isabella, V.M., Coleman, K., etal. (2013) Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature 503: 365-370.
9. DeLeon, S., Clinton, A., Fowler, H., Everett, J., Horswill, A.R., and Rumbaugh, K.P. (2014) Synergistic interactions of Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro wound model. Infect Immun 82: 4718-4728.
10. Doll, D.C., Weiss, R.B., and Issell, B.F. (1985) Mitomycin: ten years after approval for marketing. J Clin Oncol 3: 276-286.
11. Dörr, T., Vulić, M., and Lewis, K. (2010) Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biol 8: e1000317.
12. Hermansen, L., and Osnes, J.-B. (1972) Blood and muscle pH after maximal exercise in man. J Appl Physiol 32: 304-308.
13. Hsueh, P.-R., Teng, L.-J., Yang, P.-C., Pan, H.-J., Chen, Y.-C., Wang, L.-H., etal. (1999) Dissemination of two methicillin-resistant Staphylococcus aureus clones exhibiting negative staphylase reactions in intensive care units. J Clin Microbiol 37: 504-509.
14. Hu, Y., Kwan, B.W., Osbourne, D.O., Benedik, M.J., and Wood, T.K. (2015) Toxin YafQ increases persister cell formation by reducing indole signaling. Environ Microbiol 17: 1275-1285.
15. Kennedy, K.A., McGurl, J.D., Leondaridis, L., and Alabaster, O. (1985) pH dependence of mitomycin C-induced cross-linking activity in EMT6 tumor cells. Cancer Res 45: 3541-3547.
16. Kwan, B.W., Valenta, J.A., Benedik, M.J., and Wood, T.K. (2013) Arrested protein synthesis increases persister-like cell formation. Antimicrob Agents Chemother 57: 1468-1473.
17. Kwan, B.W., Osbourne, D.O., Hu, Y., Benedik, M.J., and Wood, T.K. (2015) Phosphodiesterase DosP increases persistence by reducing cAMP which reduces the signal indole. Biotechnol Bioeng 112: 588-600.
18. Lewis, K. (2007) Persister cells, dormancy and infectious disease. Nat Rev Microbiol 5: 48-56.
19. Lewis, K. (2008) Multidrug tolerance of biofilms and persister cells. Curr Top Microbiol Immunol 322: 107-131.
20. Li, L., Mendis, N., Trigui, H., Oliver, J.D., and Faucher, S.P. (2014) The importance of the viable but non-culturable state in human bacterial pathogens. Front Microbiol 5: 258.
21. Möker, N., Dean, C.R., and Tao, J. (2010) Pseudomonas aeruginosa increases formation of multidrug-tolerant persister cells in response to quorum-sensing signaling molecules. J Bacteriol 192: 1946-1955.
22. Marques, C.N.H., Morozov, A., Planzos, P., and Zelaya, H.M. (2014) The fatty acid signaling molecule cis-2-decenoic acid increases metabolic activity and reverts persister cells to an antimicrobial-susceptible state. Appl Environ Microbiol 80: 6976-6991.
23. Matsumoto, A., Vos, J.-M.H., and Hanawalt, P.C. (1989) Repair analysis of mitomycin C-induced DNA crosslinking in ribosomal RNA genes in lymphoblastoid cells from Fanconi's anemia patients. Mutat Res 217: 185-192.
24. Michel, B. (2005) After 30 years of study, the bacterial SOS response still surprises us. PLoS Biol 3: e255.
25. Mills, S.D., and Dougherty, T.J. (2012) Cell-based screening in antibacterial discovery. In Antibiotic Discovery and Development. Dougherty, T.J., and Pucci, M.J. (eds). New York, NY: Springer, pp. 901-930.
26. Pfaffl, M.W. (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
27. Ramamurthy, T., Ghosh, A., Pazhani, G.P., and Shinoda, S. (2014) Current perspectives on viable but non-culturable (VBNC) pathogenic bacteria. Front Public Health 2: 103.
28. Salem, A.M.H., Nakano, T., Takuwa, M., Matoba, N., Tsuboi, T., Terato, H., etal. (2009) Genetic analysis of repair and damage tolerance mechanisms for DNA-protein cross-links in Escherichia coli. J Bacteriol 191: 5657-5668.
29. Sanders, C.C. (1988) Ciprofloxacin: in vitro activity, mechanism of action, and resistance. Rev Infect Dis 10: 516-527.
30. Shields, C.L., Naseripour, M., and Shields, J.A. (2002) Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma. Am J Ophthalmol 133: 601-606.
31. Sun, Y., Dowd, S.E., Smith, E., Rhoads, D.D., and Wolcott, R.D. (2008) In vitro multispecies Lubbock chronic wound biofilm model. Wound Repair Regen 16: 805-813.
32. Szybalski, W., and Iyer, V.N. (1964) Crosslinking of DNA by enzymatically or chemically activated mitomycins and profiromycins, bifunctionally 'alkylating' antibiotics. Fed Proc 23: 946-957.
33. Tomasz, M. (1995) Mitomycin C: small, fast and deadly (but very selective). Chem Biol 2: 575-579.
34. Vega, N.M., Allison, K.R., Khalil, A.S., and Collins, J.J. (2012) Signaling-mediated bacterial persister formation. Nat Chem Biol 8: 431-433.
35. Weng, M.-W., Zheng, Y., Jasti, V.P., Champeil, E., Tomasz, M., Wang, Y., etal. (2010) Repair of mitomycin C mono- and interstrand cross-linked DNA adducts by UvrABC: a new model. Nucleic Acids Res 38: 6976-6984.
36. Wolcott, R., and Dowd, S. (2011) The role of biofilms: are we hitting the right target? Plast Reconstr Surg 127: 28S-35S.
37. Wood, T.K., Knabel, S.J., and Kwan, B.W. (2013) Bacterial persister cell formation and dormancy. Appl Environ Microbiol 79: 7116-7121.
38. Zajdel, M., Wagrzynowicz, Z., and Jeljaszewicz, J. (1975) Action of staphylothrombin on bovine fibrinogen. Thromb Res 6: 501-510.